Arya Roy: The effectiveness and toxicity of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Arya Roy shared a post on X:

“Excited to share our study on the effectiveness & toxicity of SG in mTNBC. T-DXd could be a viable option after SG, for those who had clinical benefit w SG!

Thanks to my co-first author Dr. Sabah Alaklabi, Shipra Gandhi & co-authors Yara Abdou, Lubna N. Chaudhary and Saba S. Shaikh.”

Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Authors:  Sabah Alaklabi, Arya Mariam Roy, Paola Zagami, Anumita Chakraborty, Nicole Held, Joseph Elijah, Anthony George, Kristopher Attwood, Saba S. Shaikh, Lubna N. Chaudhary, Yara Abdou,  and Shipra Gandhi.

Arya Mariam Roy, is a doctor of Internal Medicine who completed her residency from University of Arkansas for Medical Sciences, Little Rock. Arya is a Hematology-Oncology Fellow at Roswell Park Comprehensive Cancer Center. She is interested in solid tumors with a focus on clinical research in breast cancer, genitourinary malignancies, and neuroendocrine tumors.